BR112015027760A8 - derivados de imidazo-triazina como inibidores da pde10 - Google Patents

derivados de imidazo-triazina como inibidores da pde10

Info

Publication number
BR112015027760A8
BR112015027760A8 BR112015027760A BR112015027760A BR112015027760A8 BR 112015027760 A8 BR112015027760 A8 BR 112015027760A8 BR 112015027760 A BR112015027760 A BR 112015027760A BR 112015027760 A BR112015027760 A BR 112015027760A BR 112015027760 A8 BR112015027760 A8 BR 112015027760A8
Authority
BR
Brazil
Prior art keywords
imidazo
triazine derivatives
pde10 inhibitors
pde10
inhibitors
Prior art date
Application number
BR112015027760A
Other languages
English (en)
Portuguese (pt)
Inventor
Lyn Kormos Bethany
John Helal Christopher
Bryce Tuttle Jamison
Robert Verhoest Patrick
Allen Chappie Thomas
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR112015027760A8 publication Critical patent/BR112015027760A8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112015027760A 2013-05-02 2014-04-23 derivados de imidazo-triazina como inibidores da pde10 BR112015027760A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361818650P 2013-05-02 2013-05-02
PCT/IB2014/060945 WO2014177977A1 (en) 2013-05-02 2014-04-23 Imidazo-triazine derivatives as pde10 inhibitors

Publications (1)

Publication Number Publication Date
BR112015027760A8 true BR112015027760A8 (pt) 2018-05-08

Family

ID=50841902

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015027760A BR112015027760A8 (pt) 2013-05-02 2014-04-23 derivados de imidazo-triazina como inibidores da pde10

Country Status (33)

Country Link
US (3) US8933224B2 (https=)
EP (1) EP2991989B1 (https=)
JP (1) JP6263606B2 (https=)
KR (1) KR101770905B1 (https=)
CN (1) CN105164134B (https=)
AP (1) AP2015008843A0 (https=)
AR (1) AR096161A1 (https=)
AU (1) AU2014261070A1 (https=)
BR (1) BR112015027760A8 (https=)
CA (1) CA2910759C (https=)
CL (1) CL2015003037A1 (https=)
CR (1) CR20150591A (https=)
CU (1) CU20150144A7 (https=)
DK (1) DK2991989T3 (https=)
DO (1) DOP2015000271A (https=)
EA (1) EA027936B1 (https=)
EC (1) ECSP15050110A (https=)
ES (1) ES2637816T3 (https=)
GE (1) GEP201706675B (https=)
MA (1) MA38559B1 (https=)
MD (1) MD20150103A2 (https=)
MX (1) MX2015015163A (https=)
NI (1) NI201500157A (https=)
NZ (1) NZ712949A (https=)
PE (1) PE20151940A1 (https=)
PH (1) PH12015502462A1 (https=)
SG (1) SG11201508201VA (https=)
TN (1) TN2015000490A1 (https=)
TW (1) TWI508966B (https=)
UA (1) UA111696C2 (https=)
UY (1) UY35547A (https=)
WO (1) WO2014177977A1 (https=)
ZA (1) ZA201508968B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027936B1 (ru) * 2013-05-02 2017-09-29 Пфайзер Инк. Производные имидазотриазина в качестве ингибиторов фосфодиэстеразы 10 (pde10)
CR20190119A (es) 2016-09-09 2019-06-03 Novartis Ag Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje
CN112839648B (zh) 2018-06-07 2025-04-04 达萨玛治疗公司 Sarm1抑制剂
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
CA3155209A1 (en) * 2019-10-21 2021-04-29 Chan Mi Joung Use of imidazopyrimidine or imidazotriazine compounds for prevention, alleviation, or treatment of cognitive disorders, or for improving cognitive function
US12516064B2 (en) * 2022-02-02 2026-01-06 SpringWorks Therapeutics Inc. Tetrahydropyridopyrimidines and related analogs for inhibiting YAP/TAZ-TEAD

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
DE10130167A1 (de) 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
DE10230604A1 (de) 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
EP1651251A4 (en) 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
US20070167426A1 (en) 2004-06-02 2007-07-19 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
TW200716102A (en) 2005-06-01 2007-05-01 Wyeth Corp Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors
US20080051419A1 (en) 2006-07-26 2008-02-28 Pfizer Inc. Amine derivatives useful as anticancer agents
JP5274256B2 (ja) 2006-09-26 2013-08-28 株式会社カネカ 光学活性β−ヒドロキシ−α−アミノカルボン酸エステルの製造方法
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
EP2203171A2 (en) 2007-08-21 2010-07-07 Merck Sharp & Dohme Corp. Cb2 receptor ligands for the treatment of pain
DE102007059723A1 (de) 2007-12-12 2009-06-18 Siemens Medical Instruments Pte. Ltd. Hörvorrichtung mit Batterieklappenmodul
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
CA2716856C (en) 2008-03-20 2013-02-19 Amgen Inc. Aurora kinase modulators and method of use
KR101774035B1 (ko) * 2009-10-30 2017-09-01 얀센 파마슈티카 엔.브이. 이미다조[1,2―b]피리다진 유도체 및 PDE10 저해제로서의 그의 용도
US9073927B2 (en) 2010-01-22 2015-07-07 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Inhibitors of PI3 kinase
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2011141713A1 (en) 2010-05-13 2011-11-17 Centro Nacional De Investigaciones Oncologicas (Cnio) New bicyclic compounds as pi3-k and mtor inhibitors
MX2012013824A (es) 2010-05-28 2013-03-12 Biocryst Pharm Inc Compuestos heterociclicos como inhibidores de cinasa janus.
WO2011157793A1 (en) 2010-06-17 2011-12-22 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
KR101548443B1 (ko) * 2011-02-23 2015-08-28 화이자 인코포레이티드 신경 장애의 치료를 위한 이미다조[5,1-f][1,2,4]트라이아진
EA027936B1 (ru) * 2013-05-02 2017-09-29 Пфайзер Инк. Производные имидазотриазина в качестве ингибиторов фосфодиэстеразы 10 (pde10)

Also Published As

Publication number Publication date
US20150080401A1 (en) 2015-03-19
EA201591819A1 (ru) 2016-05-31
EP2991989A1 (en) 2016-03-09
JP6263606B2 (ja) 2018-01-17
DOP2015000271A (es) 2016-02-29
GEP201706675B (en) 2017-05-25
NI201500157A (es) 2015-11-30
EP2991989B1 (en) 2017-06-28
MX2015015163A (es) 2016-02-22
CL2015003037A1 (es) 2016-04-22
MA38559B1 (fr) 2018-04-30
AU2014261070A1 (en) 2015-10-29
CN105164134A (zh) 2015-12-16
US9145427B2 (en) 2015-09-29
KR101770905B1 (ko) 2017-08-23
ECSP15050110A (es) 2017-08-31
TN2015000490A1 (fr) 2017-04-06
AR096161A1 (es) 2015-12-09
PE20151940A1 (es) 2016-01-21
NZ712949A (en) 2017-04-28
TWI508966B (zh) 2015-11-21
CA2910759C (en) 2018-01-16
WO2014177977A1 (en) 2014-11-06
ZA201508968B (en) 2017-11-29
JP2016517877A (ja) 2016-06-20
US8933224B2 (en) 2015-01-13
DK2991989T3 (en) 2017-07-31
EA027936B1 (ru) 2017-09-29
AP2015008843A0 (en) 2015-11-30
UA111696C2 (uk) 2016-05-25
PH12015502462A1 (en) 2016-02-22
MD20150103A2 (ro) 2016-02-29
CR20150591A (es) 2016-01-04
US20150353579A1 (en) 2015-12-10
US9296761B2 (en) 2016-03-29
CU20150144A7 (es) 2016-04-25
SG11201508201VA (en) 2015-11-27
HK1213885A1 (zh) 2016-07-15
CN105164134B (zh) 2017-09-22
KR20160003234A (ko) 2016-01-08
US20140329820A1 (en) 2014-11-06
UY35547A (es) 2014-11-28
TW201506027A (zh) 2015-02-16
ES2637816T3 (es) 2017-10-17
CA2910759A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
EA201591503A1 (ru) Производные нафтиридина, полезные в качестве антагонистов альфа-v-бета-6 интегрина
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
CU24309B1 (es) Compuestos derivados tienopirimidina y composiciones farmacéuticas que los contienen
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
BR112015004111A2 (pt) novos derivados bicíclicos
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
BR112014006660A2 (pt) novos derivados de dihidroquinolina-2-ona bicíclicos
IN2015DN01315A (https=)
CR20150061A (es) Compuesto de pirazolopirimidinas
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
BR112012030473A2 (pt) pesticidas baseados em derivados pirrolidina espiroheterocíclicos
BR112016009757A8 (pt) “inibidores do vírus sincicial respiratório com base em quinazolina”
CR20140217A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas ii
BR112015029348A2 (pt) inibidores da bace
MX2017007377A (es) Compuestos organicos.
BR112015027760A8 (pt) derivados de imidazo-triazina como inibidores da pde10
EA201590561A1 (ru) Пролекарства аминохиназолинового ингибитора киназы
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
BR112016002638A2 (pt) novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório
TR201809417T4 (tr) Cb2 reseptör agonistleri olarak purin türevleri.
BR112015012825A2 (pt) piridopirazinas substituídas como inibidores de syk
BR112018001726A2 (pt) inibidores do vírus sincicial respiratório
BR112015024109A2 (pt) derivados de ureia e seu uso como inibidores de proteína de ligação de ácidos graxos (fabp)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements